Medifast, Inc. MED
13.06 USD -0.07 (-0.53%)
Nov 12, 2026, 11:05 AM EST
12.91 Day range 13.16
9.22 52-week range 13.63
- YTD
- +22.28%
- 1 year
- +12.30%
News
zacks.com Will Medifast's Metabolic Health Institute Strengthen Its Edge? MED advances its metabolic health strategy through a new Institute, proprietary science and Trilivy's phased wellness system.
benzinga.com Medifast Q3 2026 Earnings Call Transcript Medifast (NYSE:MED) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Medifast Lowers FY2026 GAAP EPS Guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) Est Medifast (NYSE:MED) lowers FY2026 GAAP EPS guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) analyst estimate..- benzinga.com Medifast Sees FY2026 Adj EPS $(0.70)-$(0.45) vs $(0.94) Est; Raises FY2026 Sales Guidance from $270.000M-$300.000M to $280.000M-$300.000M vs $287.700M Est Medifast (NYSE:MED) is looking for FY2026 Adj EPS of $(0.70)-$(0.45) vs $(0.94) analyst estimate. Raises FY2026 sales outlook from $270.000 million-$300.000 million to $280.000 million-$300.000…
benzinga.com Medifast Q3 Adj. EPS $(0.19) Beats $(0.35) Estimate, Sales $72.048M Beat $71.300M Estimate Medifast (NYSE:MED) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 9.52 percent increase over losses of $(0.21) per…
benzinga.com Medifast Sees Q4 GAAP EPS $0.00-$0.25 vs $(0.12) Est; Sees Sales $55.000M-$75.000M vs $64.100M Est Medifast (NYSE:MED) is looking for Q4 GAAP EPS of $0.00-$0.25 vs $(0.12) analyst estimate. sees sales of $55.000 million-$75.000 million vs $64.100 million analyst estimate.
benzinga.com 11 Consumer Staples Stocks Moving In Monday's After-Market Session Gainers Medifast (NYSE:MED) stock increased by 10.7% to $10.78 during Monday's after-market session. The market value of their outstanding shares is at $108.0 million. The company's, Q2 earnings came…- benzinga.com Medifast Sees Q3 GAAP EPS $(0.65)-$(0.15) vs $(0.62) Est; Sees Sales $60.000M-$80.000M vs $67.700M Est Medifast (NYSE:MED) is looking for Q3 GAAP EPS of $(0.65)-$(0.15) vs $(0.62) analyst estimate. sees sales of $60.000 million-$80.000 million vs $67.700 million analyst estimate.
benzinga.com Medifast Q2 Adj. EPS $(0.28) Beats $(0.65) Estimate, Sales $76.384M Beat $72.700M Estimate Medifast (NYSE:MED) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.65) by 56.92 percent. This is a 227.27 percent decrease over earnings of $0.22 per…- benzinga.com Medifast Launches Trilivy, Comprehensive Metabolic Health System; Co. Also Unveils Newly Formulated Meal Replacements, Including Trilivy Reset Fueling Line Enhanced With MetaVantage Technology The leading health and wellness company unveils an evolutionary transformation from weight loss to optimal metabolic health, powered by breakthrough science and human connectionMedifast, Inc.…
- benzinga.com Medifast Affirms FY2026 GAAP EPS Guidance of $(2.75)-$(1.55) vs $(1.98) Est; Affirms FY2026 Sales Guidance of $270.000M-$300.000M vs $273.700M Est Medifast (NYSE:MED) affirms FY2026 GAAP EPS guidance from $(2.75)-$(1.55) to $(2.75)-$(1.55) vs $(1.98) analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$300.000 million to…
benzinga.com Medifast Sees Q2 GAAP EPS $(1.00)-$(0.50) vs $(0.43) Est; Sees Sales $60.000M-$80.000M vs $74.700M Est Medifast (NYSE:MED) is looking for Q2 GAAP EPS of $(1.00)-$(0.50) vs $(0.43) analyst estimate. sees sales of $60.000 million-$80.000 million vs $74.700 million analyst estimate.
benzinga.com Medifast Q1 EPS $(0.19) Beats $(0.52) Estimate, Sales $76.044M Beat $69.200M Estimate Medifast (NYSE:MED) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.52) by 63.46 percent. This is a 171.43 percent decrease over losses of $(0.07) per…
benzinga.com Earnings Scheduled For May 4, 2026 
benzinga.com 12 Consumer Staples Stocks Moving In Wednesday's After-Market Session 
benzinga.com Medifast Agrees To Nominate Steamboat Capital Partners' Parsa Kiai, Jeff Rose As Independent Director Candidates Medifast, Inc. (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to…
benzinga.com Medifast Announces Availability Of OPTAVIA's Comprehensive Metabolic Health System For Reimbursement On Select Insurance Plans Using Health Savings Accounts, Flexible Spending Accounts Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible…- benzinga.com Stephens & Co. Maintains Equal-Weight on Medifast, Lowers Price Target to $12 Stephens & Co. analyst Jim Salera maintains Medifast (NYSE:MED) with a Equal-Weight and lowers the price target from $15 to $12.
benzinga.com Medifast Q4 2025 Earnings Call Transcript - benzinga.com Earnings Scheduled For February 17, 2026
benzinga.com What to Expect from Medifast's Earnings 
benzinga.com Medifast Appoints Nicholas Johnson President, Effective Immediately; CEO Dan Chard To Step Down In June Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health.Medifast…
benzinga.com Earnings Scheduled For November 3, 2025 - benzinga.com Earnings Outlook For Medifast
- benzinga.com UPDATE: Medifast Q2 EPS $0.22 Beats $(0.22) Estimate, Sales $105.600M Beat $96.100M Estimate Medifast (NYSE:MED) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $(0.22) by 200 percent. This is a 76.09 percent decrease over earnings of $0.92 per…
benzinga.com Medifast Q3 expected to be more than $(0.60) vs $(0.30) Est; Sees Q3 Sales $70.000M-$90.000M vs $93.800M Est Medifast (NYSE:MED) Q3 expected to be more than $(0.60) vs $(0.30) Est. sees Q3 sales of $70.000 million-$90.000 million vs $93.800 million analyst estimate.- benzinga.com Earnings Scheduled For August 4, 2025
- benzinga.com Is Medifast Gaining or Losing Market Support?
- benzinga.com Medifast Q2 expected to be more than $(0.55) vs $(0.08) Est; Sees Q2 Sales $85.000M-$105.000M vs $111.20M Est Medifast (NYSE:MED) Q2 expected to be more than $(0.55) vs $(0.08) Est. sees Q2 sales of $85.000 million-$105.000 million vs $111.20 million analyst estimate.
- benzinga.com Medifast Q1 EPS $(0.07) Beats $(0.27) Estimate, Sales $115.73M Beat $110.10M Estimate Medifast (NYSE:MED) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.27) by 74.07 percent. This is a 110.61 percent decrease over earnings of $0.66 per…
- benzinga.com Earnings Scheduled For April 28, 2025
- benzinga.com Uncovering Potential: Medifast's Earnings Preview
- benzinga.com How Is The Market Feeling About Medifast?
- benzinga.com DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $16.5 DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:MED) with a Neutral and lowers the price target from $17 to $16.5.
benzinga.com Trump Calls For More Tariffs, Federal Reserve Minutes On Deck: What's Driving Markets Wednesday? All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors.- benzinga.com Medifast Q1 expected to be $0 to $(0.50) vs $(0.19) Est; Sees Q1 Sales $100.000M-$120.000M vs $130.75M Est Medifast (NYSE:MED) Q1 expected to be more than $(0.50) vs $(0.19) Est. sees Q1 sales of $100.000 million-$120.000 million vs $130.75 million analyst estimate.
- benzinga.com Medifast Q4 Adj $0.10 Beats $(0.16) Estimate, Sales $119.00M Beat $114.25M Estimate Medifast (NYSE:MED) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.16) by 162.5 percent. This is a 90.83 percent decrease over earnings of $1.09 per…
- benzinga.com Earnings Scheduled For February 18, 2025
- benzinga.com Medifast Announces OPTAVIA ASCEND High-Protein, Fiber-Rich Mini Meals And Daily Nutrient Packs Aimed At Maintaining Lean Muscle Mass For GLP-1 Medication Users And Weight Management Support Two new programs incorporate OPTAVIA ASCEND products for easy nutrition, with or without medications, and provide strategies & support to help with weight maintenanceHigh-protein products help…
- benzinga.com Looking Into Medifast's Recent Short Interest
- benzinga.com DA Davidson Upgrades Medifast to Neutral, Raises Price Target to $17 DA Davidson analyst Linda Bolton Weiser upgrades Medifast (NYSE:MED) from Underperform to Neutral and raises the price target from $16.5 to $17.
- benzinga.com Medifast Sees Q4 GAAP EPS $0.10-0.65 vs $(0.18) Est; Sees Sales $100.000M-120.000M vs $129.95M Est Medifast (NYSE:MED) is looking for Q4 GAAP EPS of $0.10-0.65 vs $(0.18) analyst estimate. sees sales of $100.000 million-120.000 million vs $129.95 million estimate.
- benzinga.com Medifast Q3 2024 Adj. EPS $0.35 Beats $(0.28) Estimate, Sales $140.163M Beat $134.150M Estimate Medifast (NYSE:MED) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $(0.28) by 225 percent. The company reported quarterly sales of $140.163 million which…
- benzinga.com Medifast Q2 2024 Adj. EPS $0.92 Beats $0.39 Estimate, Sales $168.558M Miss $174.050M Estimate Medifast (NYSE:MED) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.39 by 135.9 percent. The company reported quarterly sales of $168.558 million which…
- benzinga.com DA Davidson Maintains Underperform on Medifast, Maintains $17.5 Price Target DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:MED) with a Underperform and maintains $17.5 price target.
- benzinga.com DA Davidson Downgrades Medifast to Underperform, Lowers Price Target to $17.5 DA Davidson analyst Linda Bolton Weiser downgrades Medifast (NYSE:MED) from Neutral to Underperform and lowers the price target from $25 to $17.5.
- benzinga.com Looking Into Medifast's Recent Short Interest
- benzinga.com (MED) - Analyzing Medifast's Short Interest
- benzinga.com Top 4 Defensive Stocks You'll Regret Missing This Quarter
- benzinga.com Gold Down Over 2%; 3M Profit Beats Expectations